Abstract
The first description of familial melanoma in the English literature appeared in 1820, when Norris (1) reported: It is remarkable that this gentleman’s father, about thirty years ago, died of a similar disease.... This tumour, I have remarked, originated in a mole, and it is worth mentioning, that not only my patient and his children had many moles on various parts of their bodies, but also his own father and brothers had many of them.... These facts, together with a case that has come under my notice, rather similar, would incline me to believe that this disease is hereditary. Since then, many families with a predisposition to melanoma have been described worldwide (2–5). For purposes of case definition, our laboratory curently defines familial melanoma (FMM) as a family containing >2 affected first-degree relatives with melanoma and/or pancreatic carcinoma. According to this definition, about 8–12% of melanoma is inherited as an autosomal dominant trait with variable penetrance. Affected members (AFM) of these FMM kindreds may develop multiple primary melanoma (6) and/or pancreatic cancer (7) and typically present at an earlier age than do patients with sporadic disease. In a subset of such individuals and kindreds, germline mutations of the CDKN2A gene (also known as p16INK4A and MTS1) cosegregate with cases of melanoma (2–5).
We have hypothesized that the identification of mutation carriers may in the future allow us to direct resources to the prevention and surveillance of mela noma in high-risk individuals and families. This chapter provides an overview of melanoma genetics, as well as the indications, drawbacks, and methods of germline CDKN2A mutation screening by polymerase chain reaction (PCR) amplification and automated sequencing of genomic DNA.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Norris, W. (1820) A case of fungoid disease. Edinburgh Med. Surg. J. 16, 562.
Hussussian, C. J., et al. (1994) Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15–21.
Kamb, A., et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8, 23–26.
FitzGerald, M. G., et al. (1996) Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA 93, 8541–8545.
Liu, L., et al. (1997) Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer 19, 52–54.
Monzon, J., et al. (1998) CDKN2A mutations in multiple primary melanomas. N. Engl. J. Med. 338, 879–887.
Goldstein, A. M., et al. (1995) Increased risk of pancreatic cancer in melanomaprone kindreds with p16INK4 mutations. N. Engl. J. Med. 333, 970–974.
Bale, S. J., et al. (1989) Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N. Engl. J. Med. 320, 1367–1372.
Cannon-Albright, L. A., et al. (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13–p22. Science 258, 1148–1152.
Cannon-Albright, L. A., et al. (1994) Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 23, 265–268.
Walker, G. J., et al. (1994) Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int. J. Cancer 59, 771–775.
Kamb, A., et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440.
Bergman, W., Gruis, N. A., Sandkuijl, L. A., and Frants, R. R. (1994) Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J. Invest. Dermatol. 103, 122S–125S.
Parry, D. and Peters, G. (1996) Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol. Cell. Biol. 16, 3844–3852.
Smith-Sorensen, B., and Hovig, E. (1996) CDKN2A (p16INK4A) somatic and germline mutations. Hum. Mutat. 7, 294–303.
Holland, E. A., et al. (1995) Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11, 2289–2294.
Walker, G. J., et al. (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum. Mol. Genet. 4, 1845–1852.
Kamb, A. (1995) Cell-cycle regulators and cancer. Trends Genet. 11, 136–140.
Sherr, C. J. and Roberts, J. M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–1512.
Sherr, C. J. (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984–2991.
Stone, S., etal. (1995) Complex structure and regulation of theP16 (MTS1) locus. Cancer Res. 55, 2988–2994.
Kamijo, T., Bodner, S., vande Kamp, E., Randle, D. H., and Sherr, C. J. (1999) Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217–2222.
Kamijo, T., et al. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649–659.
Watson, J. E, et al. (1999) Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res. 9, 226–233.
Czerniak, B., et al. (1999) Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18, 1185–1196.
Farrell, W. E., et al. (1997) Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res. 57, 2703–2709.
Liu, L., et al. (1999) Mutation of the CDKN2A 5’ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat. Genet. 21, 128–132.
Bahuau, M., et al. (1998) Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res. 58, 2298–2303.
Tucker, M. A., et al. (1993) Risk of melanoma and other cancers in melanomaprone families. J. Invest. Dermatol. 100, 350S–355S.
Goldstein, A. M. and Tucker, M. A. (1995) Genetic epidemiology of familial melanoma. Dermatol. Clin. 13, 605–612.
Battistutta, D., et al. (1994) Incidence of familial melanoma and MLM2 gene. Lancet 344, 1607–1608.
MacLennan, R., Green, A. C., McLeod, G. R., and Martin, N. G. (1992) Increas ing incidence of cutaneous melanoma in Queensland, Australia. J. Natl. Cancer Inst. 84, 1427–1432.
Goldstein, A. M., et al. (1994) Linkage of cutaneous malignant melanoma/ dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 54, 489–496.
Soufir, N., et al. (1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum. Mol. Genet. 7, 209–216 (published erratum appears in Hum. Mol. Genet. 1998;7[5]:941).
Zuo, L., et al. (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12, 97–99.
Traboulsi, E. I., Zimmerman, L. E., and Manz, H. J. (1988) Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch. Ophthalmol. 106, 1059–1061.
Consortium, T. B. C. L. (1999) Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310–1316.
Tucker, M. A., et al. (1997) Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 277, 1439–1444.
Greene, M. H. (1997) Genetics of cutaneous melanoma and nevi. Mayo Clin. Proc. 72, 467–474.
Hashemi, J., Linder, S., Platz, A., and Hansson, J. (1999) Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds. Melanoma Res. 9, 21–30.
Tucker, M. A., Misfeldt, D., Coleman, C. N., Clark, W. H. Jr., and Rosenberg, S. A. (1985) Cutaneous malignant melanoma after Hodgkin’s disease. Ann. Intern. Med. 102, 37–41.
Raghavan, D., et al. (1994) Multiple atypical nevi: a cutaneous marker of germ cell tumors. J. Clin. Oncol. 12, 2284–2287.
Lal, G., et al. (2000) Patients with both pancretic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes, Chromosomes, Cancer 27, 358–361.
Shennan, M. G., et al. (2000) Lack of germline CDK6 mutations in familial melanoma. Oncogene 19, 1849–1852.
Ruas, M. and Peters, G. (1998) Thep16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta. 1378, F115–F177.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Hogg, D., Liu, L., Lassam, N. (2001). Genetic Testing in Familial Melanoma. In: Nickoloff, B.J., Hood, L. (eds) Melanoma Techniques and Protocols. Methods in Molecular Medicine, vol 61. Humana Press. https://doi.org/10.1385/1-59259-145-0:109
Download citation
DOI: https://doi.org/10.1385/1-59259-145-0:109
Publisher Name: Humana Press
Print ISBN: 978-0-89603-684-0
Online ISBN: 978-1-59259-145-9
eBook Packages: Springer Protocols